Niels van de Donk
Vrije Universiteit Amsterdam
H-index: 68
Europe-Netherlands
Top articles of Niels van de Donk
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma | Clinical Cancer Research | Christie PM Verkleij Chloe A O'Neill Marloes EC Broekmans Kristine A Frerichs Wassilis SC Bruins | 2024/4/30 |
Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma | Advances in therapy | Philippe Moreau María-Victoria Mateos Maria Esther Gonzalez Garcia Hermann Einsele Valerio De Stefano | 2024/2 |
Teclistamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase II MajesTEC-1 study | Clinical Lymphoma Myeloma and Leukemia | Thomas G Martin Philippe Moreau Saad Z Usmani Alfred Garfall María-Victoria Mateos | 2024/3/1 |
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1 | Blood | Diana Cortes-Selva Tatiana Perova Sheri Skerget Deeksha Vishwamitra Sarah Stein | 2024/4/26 |
Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma | New England Journal of Medicine | Pieter Sonneveld Meletios A Dimopoulos Mario Boccadoro Hang Quach P Joy Ho | 2024/1/25 |
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma | Advances in Therapy | Hermann Einsele Philippe Moreau Nizar Bahlis Manisha Bhutani Laure Vincent | 2024/2/24 |
Monoclonal Antibodies in the Treatment of Multiple Myeloma | Acta medica Croatica: Časopis Akademije medicinskih znanosti Hrvatske | MARIJANA LISAK VANJA BAŠIĆ KES | 2018/11/16 |
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation | Blood advances | Kristine A Frerichs Christie PM Verkleij Maria Victoria Mateos Thomas G Martin Cesar Rodriguez | 2024/1/9 |
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review | Paula Rodriguez-Otero Niels WCJ van de Donk Kodandaram Pillarisetti Ingrid Cornax Deeksha Vishwamitra | 2024/2/2 | |
Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | 2023/9/21 | ||
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review | Paula Rodriguez-Otero Niels WCJ van de Donk Kodandaram Pillarisetti Ingrid Cornax Deeksha Vishwamitra | 2024/12 | |
Loss of vision as the first manifestation of amyloid light‐chain amyloidosis | eJHaem | Niels WCJ van de Donk Clément Huysentruyt Mario RP Dhooge | 2024 |
The Phase 2 Cartitude-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1–3 Prior Lines of Therapy (Cohort A) and with … | Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy | Jens Hillengass Adam D Cohen Mounzer Agha Michel Delforge Tessa Kerre | 2024/2/1 |
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting | Clinical Lymphoma Myeloma and Leukemia | Noopur S Raje Adam D Cohen Krina K Patel Niels WCJ van de Donk Joshua Richter | 2024/3/22 |
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma | The Lancet Oncology | Paula Rodriguez-Otero Saad Usmani Adam D Cohen Niels WCJ van de Donk Xavier Leleu | 2024/5/1 |
Clinical Experience with Cranial Nerve Impairment in the Cartitude-1, Cartitude-2 Cohorts a, B and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel) | Transplantation and Cellular Therapy | Niels WCJ van de Donk Surbhi Sidana Jordan M Schecter Carolyn C Jackson Nikoletta Lendvai | 2024/2/1 |
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study | Cancer | Ajay K Nooka Cesar Rodriguez María Victoria Mateos Salomon Manier Katherine Chastain | 2024/3/15 |
Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in … | Paula Rodríguez-Otero Carolina D Schinke Ajai Chari Brea Lipe Noa Lavi | 2023/6/1 | |
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results … | HemaSphere | Kazimierz Groen Fredrik H Schjesvold Bronno Van Der Holt Mark-David Levin Maarten R Seefat | 2023/9/1 |
S191: pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (bsab), for relapsed/refractory multiple myeloma (RRMM) | Hemasphere | Cyrille Touzeau Carolina Schinke Monique Minnema Niels WCJ Van De Donk Paula Rodríguez-Otero | 2023/8/1 |
